why does nobody talk about non-peptide
Genuine question, and the title is the question: why does nobody talk about non-peptide.
The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.
Assumed the peptide purity conversations transferred and they do not. Different analytical problem entirely.
Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.
Would rather be corrected in public than confident in private.
best — the order this archive was captured in
Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different.
Went looking for independent testing on this and found essentially nothing, which was clarifying.
This. The absence of food and water timing restrictions is the practical difference people will actually notice.
What did the tolerability table look like at that dose?
That is a phase 2 result being quoted as though the programme had reported.
I would not assume the tolerability profile transfers exactly. Similar class effects, different exposure profile.
I would not assume the tolerability profile transfers exactly.
Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.
What is actually known, and what is being assumed.
Known: it is a small-molecule GLP-1 receptor agonist, dosed daily, with clinical programmes reporting in both obesity and type 2 diabetes. Its tolerability profile broadly resembles the class in the data published so far.
Assumed, frequently and confidently: that milligram comparisons with injectables mean something, that adherence is straightforwardly better because it is a tablet, that peptide purity discussions transfer to it. None of those hold. And nothing containing this compound is approved anywhere, which makes research-use-only material exactly that — not approved for human use.
Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.
Agreed that phase 3 is where the comparison becomes fair.
Agreed, and it is why the oral peptide comparison keeps misleading people.
Right, and comparing milligrams between a small molecule and a peptide is meaningless in either direction.
Correcting myself: that was a phase 2 readout and I described it as phase 3.
Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction.
Careful — purity methods for peptides do not read across to a small molecule and the numbers are not equivalent.
Which programme and which readout are you quoting?
- 1What is actually known, and what is being assumed. Known: it is a…6 comments in this branch · started by u/trialwatch_theo